Patent classifications
C07C259/18
FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT
The purpose of the present invention is to provide an excellent agricultural or horticultural plant disease control agent. Provided are: a formamide derivative represented by general formula [I] and the like (in the formula, X.sup.1, X.sup.2, X.sup.3, and X.sup.4 each independently represents a carbon atom and the like, Y represents an oxygen atom or a sulfur atom, R.sup.1 represents a halogen atom, and R.sup.2 represents a hydrogen atom, a C.sub.1-C.sub.6 alkyl group, and the like) or an agriculturally acceptable salt thereof; and an agricultural or horticultural plant disease control agent containing the same as an active ingredient.
##STR00001##
BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME
Disclosed are compounds of formulae:
##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are usefl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME
Disclosed are compounds of formulae:
##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are usefl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
Orally bioavailable pentamidine prodrugs for the treatment of diseases
The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.
Orally bioavailable pentamidine prodrugs for the treatment of diseases
The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.
Benzamides and related inhibitors of factor XA
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Benzamides and related inhibitors of factor XA
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Opsin-Binding Ligands, Compositions and Methods for Use
Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.